← Back to home

NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY

Clinical trials for NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY explained in plain language.

Never miss a new study

Get alerted when new NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY trials appear

Sign up with your email to follow new studies for NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Could immunotherapy let some stomach cancer patients skip surgery?

Disease control Not yet recruiting

This study looks at whether a combination of two immunotherapy drugs (Durvalumab and Tremelimumab) can control advanced stomach cancers with specific genetic features (dMMR/MSI-H) well enough to avoid surgery. The trial enrolls 12 adults who would normally need chemotherapy and s…

Matched conditions: NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY

Sponsor: Yong Zhou • Aim: Disease control

Last updated Jun 27, 2026 13:06 UTC

NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY

Get alerted when new NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY trials appear

Could immunotherapy let some stomach cancer patients skip surgery?